

DAFTAR PUSTAKA

- Arbyn, M., Castellsagué, X., Bray, F., 2011. Worldwide burden of cervical cancer in 2008. *Ann. Oncol.* 22 22: 2675–2686.
- Arsyad, N.R., 2018. Hubungan Antara Ekspresi P53 Mutan Terhadap Operabilitas Kanker Serviks Stadium IIB Pasca Kemoterapi Neoajuvan. FK UGM, Jogjakarta.
- Aster, V.K.-A.K.A.-J.C., 2015. Buku Ajar Patologi Robbins, 9th ed. Elseiver, Singapura.
- Aziz, M.F., 2009. Gynecological cancer in Indonesia. *J Gynecol Oncol* 20: 8–10.
- Badan Penelitian dan Pengembangan Kesehatan Kementerian Kesehatan, 2013. Riset Kesehatan Dasar (RISKESDAS) 2013.
- Bae, H.S., Kim, Y.J., Lim, M.C., Seo, S.S., Park, S. yoon, Kang, S., Kim, S.H., Kim, J.Y., 2016. Predictors of radiation field failure after definitive chemoradiation in patients with locally advanced cervical cancer. *Int. J. Gynecol. Cancer* 26: 737–742.
- Bahnassy, A.A., Zekri, A.R.N., Saleh, M., Lotayef, M., Moneir, M., Shawki, O., 2007. The possible role of cell cycle regulators in multistep process of HPV-associated cervical carcinoma 11: 1–11.
- Bai, L., Guo Zhu, W., 2006. p53: Structure, Function and Therapeutic Applications. *J. Cancer Mol.* 4: 141–153.
- Bhatla, N., Aoki, D., Sharma, D.N., Sankaranarayanan, R., 2018. FIGO Cancer Report 2018. Cancer of the cervix uteri. *Int. J. Gynecol. Obstet.* 143: 22–36.
- Chen, H., Liang, C., Zhang, L., Huang, S., Wu, X., 2008. Clinical Efficacy of Modified Preoperative Neoadjuvant Chemotherapy in the Treatment of Locally Advanced (Stage IB2 to IIB) Cervical Cancer: Randomized Study. *Gynecol. Oncol.* 110: 308–315.
- Cibula, D., Potter, R., Raspollini, M.R., Avall-Lundqvist, E., Fischerova, D., Meder, C.H., Kohler, C., Landoni, F., 2018. Cervical Cancer Guideline. ESGO.
- Dasari, S., Bernard, P., 2014. Cisplatin in cancer therapy : Molecular mechanisms of action. *Eur. J. Pharmacol.* 1–15.
- de Sanjosé, S., Brotons, M., Pavón, M.A., 2018. The natural history of human papillomavirus infection. *Best Pract. Res. Clin. Obstet. Gynaecol.* 47: 2–13.
- DeVita, V.T., Lawrence, T.S., Rosenberg, S.A., 2008. *Cancer, Principles and Practice on Oncology*, 8th ed. Lippincott Williams & Wilkins, Philadelphia.

- Di Saia, P.J., Creasman, W.T., 2012. *Clinical Gynecologic Oncology*, eight. ed. elseiver, China.
- Eisenhauer, E.A., Therasse, P., Bogaerts, J., Schwartz, L.H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., Rubinstein, L., Shankar, L., Dodd, L., 2008. New response evaluation criteria in solid tumours : Revised RECIST guideline (version 1 . 1). *Eur. J. Cancer* 45: 228–247.
- Fayad, D.W.S.A.-, 2010. Immunohistochemical Expression of P53 In Different Types of Ameloblastoma Conclusion : Al- Anbar Med. J. 8: 66–73.
- Florea, A.-M., Busselberg, D., 2011. Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects 1351–1371.
- Freier, C.P., Stiasny, A., Kuhn, C., Mayr, D., Alexiou, C., Janko, C., Wiest, I., Jeschke, U., Kost, B., 2016. Immunohistochemical evaluation of the role of p53 mutation in cervical cancer: Ser-20 p53-mutant correlates with better prognosis. *Anticancer Res.* 36: 3131–3137.
- Galic, V., Herzog, T.J., Lewin, S.N., Neugut, A.I., Burke, W.M., Lu, Y.S., Hershman, D.L., Wright, J.D., 2012. Prognostic significance of adenocarcinoma histology in women with cervical cancer. *Gynecol. Oncol.* 125: 287–291.
- Gholap, Devyani, C.P., Dikshit, Rajesh, 2018. Ecological Analysis to Study Association between Prevalence of Smokeless Tobacco Type and Head-and-Neck Cancer. *Indian J. Med. Paediatr. Oncol.*
- Gómez, D.T., Santos, J.L., 2007. Human Papillomavirus Infection And Cervical Cancer: Pathogenesis And Epidemiology 680–688.
- Gupta, S., Maheshwari, A., Parab, P., Mahantshetty, U., Hawaldar, R., Sastri, S., 2019. Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Concomitant Chemotherapy and Radiotherapy in Patients With Stage IB2 , IIA , or IIB Squamous Cervical Cancer : A Randomized Controlled Trial 36.
- Habbous, S., Pang, V., Eng, L., Xu, W., Kurtz, G., Liu, F.F., Mackay, H., Amir, E., Liu, G., 2012. p53 Arg72Pro Polymorphism, HPV Status and Initiation, Progression, and Development of Cervical Cancer: A Systematic Review and Metaanalysis. *Clin. Cancer Res.* 18: 6407–6415.
- Hientz, K., Mohr, A., Bhakta-Guha, D., Efferth, T., 2017. The role of p53 in cancer drug resistance and targeted chemotherapy. *Oncotarget* 8: 8921–8946.
- Hu, T., Li, S., Chen, Y., Shen, J., Li, X., Huang, K., Song, X., Tian, X., Xu, H., Xu, J., Zhang, Q., Wang, C., Xie, X., Ma, D., 2012. Matched-case Comparison of Neoadjuvant Chemotherapy in Patients with FIGO Stage IB1-IIB Cervical Cancer to Establish Selection Criteria. *Eur. J. Cancer* 48: 2353–2360.
- Kasamatsu, T., Onda, T., Sawada, M., Kato, T., Ikeda, S., 2009. Radical

Hysterectomy for FIGO stage IIB Cervical Cancer: Clinicopathological Characteristics and Prognostic Evaluation. *Gynecol. Oncol.* 114: 69–74.

Katsumata, N., Yoshikawa, H., Kobayashi, H., Saito, T., Kuzuya, K., Nakanishi, T., Yasugi, T., Yaegashi, N., 2013. Phase III Randomised Controlled Trial of Neoadjuvant Chemotherapy plus Radical Surgery vs Radical Surgery alone for Stages IB2, IIA2, and IIB Cervical Cancer: a Japan Clinical Oncology Group Trial (JCOG 0102). *Br. J. Cancer* 108: 1957–1963.

Khunamornpong, S., Siriaunkgul, S., Manusirivithaya, S., Settakorn, J., Srisomboon, J., Ponjaroen, J., Thorner, P.S., 2008. Prognostic value of p53 expression in early stage cervical carcinoma treated by surgery. *Asian Pac J Cancer Prev* 9: 48–52.

Kumar, L., Gupta, S., 2016. Integrating Chemotherapy in the Management of Cervical Cancer: A Critical Appraisal. *Oncol. Rev.* 91: 8–17.

Kurnia, I., Siregar, B., Soetopo, S., 2015. Correlation Between Akt and p53 Protein Expression and Chemoradiotherapy Response in Cervical Cancer Patients. *Hayati J. Biosci.* 21: 173–179.

Li, X., Huang, K., Zhang, Q., Shen, J., Zhou, H., Du, X., Wang, H., Deng, S., Ding, T., Jiang, J., 2016. Early response to neoadjuvant chemotherapy can help predict long-term survival in patients with cervical cancer 7: 87485–87495.

Liu, L., Li, X.D., Chen, H.Y., Cui, J.S., Xu, D.Y., 2015. Significance of Ebp1 and p53 protein Expression in Cervical Cancer 14: 11860–11866.

Ma, S., Wang, J., Han, Y., Guo, F., Chen, C., Chen, X., Zou, W., 2019. Gynecologic Oncology Platinum single-agent vs . platinum-based doublet agent concurrent chemoradiotherapy for locally advanced cervical cancer: A meta-analysis of randomized controlled trials. *Gynecol. Oncol.* 154: 246–252.

Matsuo, K., Mandelbaum, R.S., Machida, H., Purushotham, S., Grubbs, B.H., Roman, L.D., Wright, J.D., 2018. Association of tumor differentiation grade and survival of women with squamous cell carcinoma of the uterine cervix. *J. Gynecol. Oncol.* 29: 1–12.

Mohanta, S., Siddappa, G., Valiyaveedan, S.G., Ramanjanappa, R.D.T., Das, D., Pandian, R., Khora, S.S., Kuriakose, M.A., Suresh, A., 2017. Cancer stem cell markers in patterning differentiation and in prognosis of oral squamous cell carcinoma. *Tumor Biol.* 39.

Osman, M., 2014. The Role of Neoadjuvant Chemotherapy in Management of Locally Advanced Cancer Cervix: A Systemic Review. *Oncol. Rev.* 8.

Panici, P.B., Scambia, G., Baiocchi, G., Greggi, S., Ragusa, G., Gallo, A., Conte, M., Battaglia, F., Laurelli, G., Rabitti, C., Capelli, A., Mancuso, S., 1991. Neoadjuvant chemotherapy and radical surgery in locally advanced cervical cancer. Prognostic factors for response and survival. *Cancer* 67: 372–379.

- Prakosa, T., Askandar, B., Fauziah, D., 2013. Ekspresi p53 Mutan dan Caspase 3 sebagai Faktor Prediksi terhadap Operabilitas Kanker Serviks IIB setelah Mendapat Kemoterapi Neoadjuvan. *Indones. J. Cancer* 7: 61–67.
- Puty Hariandy, R., Dina, S., Edianto, D., 2017. Hubungan Ekspresi VEGF Dengan Respon Kemoterapi Neoadjuvan Ifosfamide-Cisplatin Pada Kanker Serviks Stadium IB-IIA. FK USU, Medan.
- Rasjidi, I., 2009. *Epidemiologi Kanker Serviks III*: 103–108.
- Reles, A., Wen, W.H., Schmider, A., Gee, C., Runnebaum, I.B., Kilian, U., Jones, L.A., El-naggar, A., Minguillon, C., Scho, I., Reich, O., Kreienberg, R., Lichtenegger, W., Press, M.F., 2001. Advances in Brief Correlation of p53 Mutations with Resistance to Platinum-based Chemotherapy and Shortened Survival in Ovarian Cancer 1. *Clin. Cancer Res.* 7: 2984–2997.
- RI, K.K., Kementrian Kesehatan RI Pusat Data dan Informasi Kesehatan, 2015. STOP KANKER, Situasi penyakit kanker.
- Rose, P.G., Java, J.J., Whitney, C.W., Stehman, F.B., Lanciano, R., Thomas, G.M., 2014. Locally advanced adenocarcinoma and adenosquamous carcinomas of the cervix compared to squamous cell carcinomas of the cervix in Gynecologic Oncology Group trials of cisplatin-based chemoradiation. *Gynecol. Oncol.* 135: 208–212.
- Rydzewska, L., Tierney, J., Cl, V., Pr, S., 2015. Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer (Review).
- Rydzewska, L., Tierney, J., Cl, V., Pr, S., 2010. Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer (Review).
- Saito, T., Takehara, M., Tanaka, R., Lee, R., Horie, M., Wataba, K., Ito, E., Kudo, R., 2004. Correlation between responsiveness of neoadjuvant chemotherapy and apoptosis-associated proteins for cervical adenocarcinoma. *Gynecol. Oncol.* 92: 284–292.
- Sandhu, J.K., Shivakumar, S., 2016. Study of p53 in Cervical Intraepithelial Neoplasia and Carcinoma Cervix with Clinico-pathological Correlation. *Int. J. Sci. Study* 4: 208–214.
- Sardi, J.E., Paola, G.R.D.I., Cachalj, A., 1986. A Possible New Trend in the Management of the Carcinoma of the Cervix Uteri 49.
- Scandurra, G., Scibilia, G., Banna, G.L., D'Agate, G., Lipari, H., Gieri, S., Scollo, P., 2015. Efficacy and tolerability of paclitaxel, ifosfamide, and cisplatin as a neoadjuvant chemotherapy in locally advanced cervical carcinoma. *J Gynecol Oncol* 26: 118–124.
- Siegel, R.L., Miller, K.D., Jemal, A., 2016. *Cancer Statistics*, 2016 66: 7–30.
- Siswosudarmo, R., 2015. Pendekatan Praktis Penelitian Epidemiologi Klinis dan Aplikasi SPSS untuk Analisis Statistika. Bagian Obstetrika dan Ginekologi

Fakultas Kedokteran Universitas Gadjah Mada Yogyakarta, Yogyakarta.

Suhatno, Sunjoto, Hartono, P., Askandar, B., Saraswati, W., Yuliati, I., 2018. Pedomannya Nasional Pelayanan Kedokteran Kanker Serviks. Indonesia.

Wiebe, E., Denny, L., Thomas, G., 2012. FIGO Cancer Report 2012 Cancer of the cervix uteri. *Int J Gynecol Obs.* 119S2 2: 100–109.

Wresti Indriatmi, A. (Ed.), 2013. Infeksi Human Papillomavirus. Badan Penerbit FKUI, Jakarta.

Yang, L., Guo, J., Shen, Y., Cai, J., Xiong, Z., Dong, W., Min, J., Wang, Z., 2015. Clinical efficacy and safety of paclitaxel plus carboplatin as neoadjuvant chemotherapy prior to radical hysterectomy and pelvic lymphadenectomy for Stage IB 2 -IIB cervical cancer 8: 13690–13698.

Zhou, R., Wei, C., Liu, J., Luo, Y., Tang, W., 2015. *European Journal of Obstetrics & Gynecology and Reproductive Biology* The prognostic value of p53 expression for patients with cervical cancer : a meta analysis. *Eur. J. Obstet. Gynecol.* 195: 210–213.